Nasdaq:US$14.03 (-0.15) | HKEX:HK$21.92 (-0.90) | AIM:£2.17 (-0.01)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Leadership
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Dissemination of Corporate Communications
Modern Slavery and Human Trafficking Statement
Career
About Us
Overview
Corporate Information
Board of Directors
Leadership
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Dissemination of Corporate Communications
Modern Slavery and Human Trafficking Statement
Career
News & Presentations
Hutchmed
| News & Presentations
News & Press Releases
5 Nov 2025
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS
®
and TAGRISSO
®
Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO
®
Read more
3 Nov 2025
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
Read more
23 Oct 2025
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Read more
13 Oct 2025
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
Read more
Scientific Publications
13 Jan 2025
Targeted Oncology: Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial
Read more
11 Sep 2024
THE LANCET Respiratory Medicine: Savolitinib Phase IIIb confirmatory study in treatment-naive METex14 NSCLC patients in China
Read more
17 Jun 2024
THE LANCET Haematology: Efficacy and safety of sovleplenib in adult patients with chronic primary ITP in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
Read more
3 Jun 2024
Nature Medicine : Fruquintinib plus paclitaxel for gastric/ gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
Read more
Mailing List Sign-up
If you would like to be kept up to date with the latest news of HUTCHMED, please sign up to our mailing list . We will deliver the relevant material directly to your email box as soon as it becomes available online.